Form 7 Monthly Progress Report December 2025
Form 7 Monthly Progress Report December 2025 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 105,090,213 January 5, 2025 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors
BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors Expanding U.S. market access with an experienced technology investor and AI-driven growth strategist VANCOUVER, BRITISH COLUMBIA – (December 30, 2025) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early […]
BioMark: 2025 Achievements & 2026 Vision
BioMark: 2025 Achievements & 2026 Vision Celebrating A Year of Extraordinary Achievement VANCOUVER, BRITISH COLUMBIA – (December 31, 2025) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early cancer detection, today issued a Year-End Letter to Shareholders and Team from its […]
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program Company engages Standards Council of Canada; targets ISO 15189 accreditation for early 2026 Vancouver, British Columbia – (December 23, 2025) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to […]
BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
Recognition of BioMark Leadership in Early Cancer Detection Validates Commercialization Trajectory of Multimodal Lung Cancer Screening Platform Vancouver, British Columbia – (December 1st, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early cancer detection, is honored to announce that the Company and its […]
Form 7 Monthly Progress Report November 2025
Form 7 Monthly Progress Report September 2025 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 105,090,213 December 2, 2025 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy
Next-generation metabolomics and AI technology supports the 2026 – 2035 Pan-Canadian Lung Cancer Action Plan’s call to expand equitable access to life-saving early diagnosis Vancouver, British Columbia – (November 12, 2025) – November is Lung Cancer Awareness Month, and BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy […]
Form 7 Monthly Progress Report October 2025
Form 7 Monthly Progress Report September 2025 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 105,090,213 November 1, 2025 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
BioMark’s Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial
BioMark’s Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial Extensive Validation of BioMark’s Comprehensive Metabolic Panel in German 10,000-Participant HANSE Study, within the context of an international consortium supported under the EUREKA Network. Vancouver, British Columbia – (October 7, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a […]
Form 7 Monthly Progress Report September 2025
Form 7 Monthly Progress Report September 2025 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 105,090,213 October 5, 2025 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]